WO2023064435A3 - Compositions and methods relating to sars-cov-2 neutralizing antibodies - Google Patents

Compositions and methods relating to sars-cov-2 neutralizing antibodies Download PDF

Info

Publication number
WO2023064435A3
WO2023064435A3 PCT/US2022/046513 US2022046513W WO2023064435A3 WO 2023064435 A3 WO2023064435 A3 WO 2023064435A3 US 2022046513 W US2022046513 W US 2022046513W WO 2023064435 A3 WO2023064435 A3 WO 2023064435A3
Authority
WO
WIPO (PCT)
Prior art keywords
sars
cov
compositions
neutralizing antibodies
methods relating
Prior art date
Application number
PCT/US2022/046513
Other languages
French (fr)
Other versions
WO2023064435A2 (en
Inventor
Frederick W. Alt
Sai Luo
Kevin SAUNDERS
Barton F. Haynes
Original Assignee
The Children's Medical Center Corporation
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Children's Medical Center Corporation, Duke University filed Critical The Children's Medical Center Corporation
Publication of WO2023064435A2 publication Critical patent/WO2023064435A2/en
Publication of WO2023064435A3 publication Critical patent/WO2023064435A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The ongoing COVID-19 pandemic and the previous SARS outbreak: highlight the danger of recurrent human infections by the emergence of novel pathogenic variants of Coronavirus, which may be resistant to pre-existing human immunity and available vaccines or drugs. Accordingly, described herein is the creation of antibodies that specifically bind S proteins from SARS Co V-2 and related viruses in this family. Described herein are antibody reagents that bind therapeutic targets such as SARS-COV2 spike protein, as well as methods of using such antibody reagents.
PCT/US2022/046513 2021-10-15 2022-10-13 Compositions and methods relating to sars-cov-2 neutralizing antibodies WO2023064435A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163256384P 2021-10-15 2021-10-15
US63/256,384 2021-10-15
US202263305424P 2022-02-01 2022-02-01
US63/305,424 2022-02-01
US202263346654P 2022-05-27 2022-05-27
US63/346,654 2022-05-27

Publications (2)

Publication Number Publication Date
WO2023064435A2 WO2023064435A2 (en) 2023-04-20
WO2023064435A3 true WO2023064435A3 (en) 2023-07-27

Family

ID=85988874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/046513 WO2023064435A2 (en) 2021-10-15 2022-10-13 Compositions and methods relating to sars-cov-2 neutralizing antibodies

Country Status (1)

Country Link
WO (1) WO2023064435A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011036435A1 (en) * 2009-09-22 2011-03-31 The Secretary Of State For Defence Anti-veev humanized antibody
WO2017189959A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US20200308291A1 (en) * 2015-09-16 2020-10-01 Ablexis, Llc Anti-cd115 antibodies
WO2020223573A2 (en) * 2019-04-30 2020-11-05 Gigagen, Inc. Recombinant polyclonal proteins and methods of use thereof
WO2021045836A1 (en) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011036435A1 (en) * 2009-09-22 2011-03-31 The Secretary Of State For Defence Anti-veev humanized antibody
US20200308291A1 (en) * 2015-09-16 2020-10-01 Ablexis, Llc Anti-cd115 antibodies
WO2017189959A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2020223573A2 (en) * 2019-04-30 2020-11-05 Gigagen, Inc. Recombinant polyclonal proteins and methods of use thereof
WO2021045836A1 (en) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments

Also Published As

Publication number Publication date
WO2023064435A2 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
GT201200271A (en) PROTEINS THAT JOIN TNF-A
EA201892793A1 (en) ANTI-HLA-G SPECIFIC ANTIBODIES
EP2336174A3 (en) Human monoclonal antibodies against Hendra and Nipah viruses
BR112014004860A2 (en) influenza virus antibody compositions
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
EA201000424A1 (en) ANTIBODIES TO IL-23
BR0211296A (en) Immunogenic peptide derived from subgroup a or b vrs protein g, nucleic acid sequence, pharmaceutical composition, polyclonal or monoclonal antibodies, diagnostic kit, use of an immunogenic peptide, and, conjugate
BR112019005726A8 (en) ANTIGEN-BINDING ANTIBODY OR FRAGMENT OF THE SAME WHICH BINDS HUMAN CD27, ISOLATED POLYPEPTIDE, ISOLATED NUCLEIC ACID, EXPRESSION VECTOR, HOST CELL, COMPOSITION, METHODS OF PRODUCING AN ANTIBODY OR AN ANTIGEN-BINDING FRAGMENT, OF TREATMENT OF CANCER AND TREATMENT OF AN INFECTION OR INFECTIOUS DISEASE, AND USE OF THE ANTIBODY OR ANTIGEN-BINDING FRAGMENT
MA32365B1 (en) Combined derivatives of cyclopentane carboxylic acid substituted by acyl amino, and used as drugs
WO2012021786A3 (en) Anti-hemagglutinin antibody compositions and methods of use thereof
BR112012027055A2 (en) stabilizing agent for pharmaceutical proteins.
BRPI0821110B8 (en) anti-nr10/il31ra neutralizing antibody, pharmaceutical composition comprising said antibody and use thereof
BR112015022210A8 (en) antibody formulations
EA200970586A1 (en) HUMAN CYTOMEGAL VIRUS ANTIBODIES (HCMV)
BR112019016300A2 (en) ANTI-FXI OR ANTI-FXIa ANTIBODY, ITS USE AND METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITION AND ANTIBODY OR A FUNCTIONAL FRAGMENT OF THE SAME OR AN IMMUNOLOGICALLY ACTIVE PORTION OF THE SAME
CL2020002012A1 (en) Human anti-rankl antibody formulations and methods of using them. (divisional request 201903032)
MA32388B1 (en) IMMUNOMODULATION WITH IPA INHIBITORS
BR0012919A (en) Vaccine for use in the prophylaxis and / or treatment of white spot syndrome in crustaceans, structural protein derived from white point syndrome virus, nucleic acid sequence, use of a structural protein, pharmaceutical composition, antibodies, vaccine or pharmaceutical formulation, and, diagnostic kit for wssv detection
EA201300132A1 (en) PHARMACEUTICAL COMPOSITION AND METHODS OF TREATMENT AND PREVENTION OF DISEASES CAUSED BY HIV OR ASSOCIATED WITH HIV
BR112022024149A2 (en) ANTI-SARS-COV-2 SPIKE ANTI-GLYCOPROTEIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
BR112018008840A2 (en) single domain antibodies directed against intracellular antigens
WO2022167816A3 (en) Antibodies
EP2495252A3 (en) Soluble forms of hendra and nipah virus G glycoprotein
BRPI0504117A (en) epitopes, combination of epitopes, uses of epitopes or their combination, composition, uses of composition, anti-HIV-1 prophylactic vaccines, therapeutic vaccines, method for identifying epitopes and methods for treatment or prevention.
BR102016012501A2 (en) peptide, pharmaceutical composition, use of the peptide, and, use of the pharmaceutical composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22881752

Country of ref document: EP

Kind code of ref document: A2